• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders

    4/6/26 8:39:25 AM ET
    $NXTS
    Agricultural Chemicals
    Industrials
    Get the next $NXTS alert in real time by email
    false --12-31 0001789192 0001789192 2026-04-03 2026-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 3, 2026

     

    Nexentis Technologies Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-40403   26-4684680

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    Pinhas Sapir St. 3, Kiryat HaMada

    Ness Ziona 7403626, Israel

      4994500
    (Address of principal executive offices)   (Zip Code)

     

    (347) 468 9583

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former Name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001   NXTS   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.03 Material Modifications to Rights of Security Holders.

     

    As previously reported on the Current Report on Form 8-K filed by Nexentis Technologies Inc. (the “Company”) with the Securities and Exchange Commission on September 25, 2025, at the special meeting of stockholders of the Company held on said date, the stockholders approved a proposal authorizing the Company’s board of directors (the “Board”), in its sole discretion, to amend the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), at any time within one year after stockholder approval is obtained, to effect a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), by a ratio of no less than 1-for-2 and no more than 1-for-150, with the exact split ratio to be determined by the Board in its sole discretion without further approval or authorization of the Company’s stockholders. After the special meeting, the Board determined that it is in the best interests of the Company and its stockholders to effectuate a reverse stock split of the Common Stock at a ratio of one-for-seven (1-for-7) (the “Reverse Stock Split”).

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On April 3, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada, to effect the Reverse Stock Split. The Certificate of Amendment will become effective on April 7, at 4:15 p.m. Eastern Daylight Time.

     

    Upon the opening of the market on April 8, 2026, the Common Stock will begin trading on the Nasdaq Capital Market (“Nasdaq”) on the post-Reverse Stock Split basis under the current symbol “NXTS” but with a new CUSIP number.

     

    As a result of the Reverse Stock Split, every seven (7) shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split will be rounded up to the next whole number. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 5,111,362 shares to approximately 730,309 shares, subject to adjustment for the rounding up of fractional shares. The Common Stock issued pursuant to the Reverse Stock Split will remain fully paid and non-assessable. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, convertible notes, and warrants, as applicable. The Reverse Stock Split will not affect the number of authorized shares of Common Stock or the par value of the Common Stock nor will it change the authorized shares of preferred stock or the relative voting power of holders of the outstanding Common Stock. The number of authorized shares of Common Stock under the Certificate of Amendment will remain unchanged at 495,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, $0.0001 par value per share, none of which is issued and outstanding.

     

    The Company’s transfer agent, Securities Transfer Corporation, is acting as the exchange agent for the Reverse Stock Split and will send instructions to stockholders of record regarding the exchange of certificates of Common Stock if the shares were issued in certificated form.

     

    Except for de minimis adjustments that result from the treatment of fractional shares, the Reverse Stock Split does not have any immediate dilutive effect on our stockholders, since each stockholder holds the same percentage of Common Stock outstanding immediately following the Reverse Stock Split as such stockholder held immediately prior to the Reverse Stock Split.

     

    A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference. The information set forth in Item 3.03 of this Current Report is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Nexentis Technologies Inc. filed April 3, 2026, effective as of April 7, 2026.
    104   Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Nexentis Technologies Inc.
         
    Date: April 6, 2026 By: /s/ David Palach
      Name: David Palach
      Title: Chief Executive Officer

     

     

    Get the next $NXTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXTS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lee Eun Young

    4 - Nexentis Technologies Inc. (0001789192) (Issuer)

    3/26/26 4:35:16 PM ET
    $NXTS
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by new insider Lee Eun Young

    3 - Nexentis Technologies Inc. (0001789192) (Issuer)

    3/23/26 4:03:55 PM ET
    $NXTS
    Agricultural Chemicals
    Industrials

    $NXTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform

    Visit Nexentis at: www.nexentistech.com Neve Yarak, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, is proud to announce the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company's recent rebranding from N2OFF, Inc., and underscores its commitment to advancing mitochondrial biology for breakthroughs in precision oncology and inflammatory metabolic diseases. The newly launched website serves as a comprehensive hub for stakeholders, including investors,

    3/13/26 9:15:00 AM ET
    $NXTS
    Agricultural Chemicals
    Industrials

    $NXTS
    SEC Filings

    View All

    SEC Form S-3 filed by Nexentis Technologies Inc.

    S-3 - Nexentis Technologies Inc. (0001789192) (Filer)

    4/16/26 4:15:33 PM ET
    $NXTS
    Agricultural Chemicals
    Industrials

    Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders

    8-K - Nexentis Technologies Inc. (0001789192) (Filer)

    4/6/26 8:39:25 AM ET
    $NXTS
    Agricultural Chemicals
    Industrials

    SEC Form 10-K filed by Nexentis Technologies Inc.

    10-K - Nexentis Technologies Inc. (0001789192) (Filer)

    3/31/26 4:16:05 PM ET
    $NXTS
    Agricultural Chemicals
    Industrials